Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for Orchestra BioMed Holdings (OBIO) over the last 2 years, with Dec 2024 value amounting to $416,368.

  • Orchestra BioMed Holdings' Gains from Sales and Divestitures rose 538.31% to $922,848 in Q3 2025 from the same period last year, while for Sep 2025 it was $922,848, marking a year-over-year increase of 538.31%. This contributed to the annual value of $416,368 for FY2024, which is 415.37% up from last year.
  • According to the latest figures from FY2024, Orchestra BioMed Holdings' Gains from Sales and Divestitures is $416,368, which was up 415.37% from $80,790 recorded in FY2023.
  • Orchestra BioMed Holdings' Gains from Sales and Divestitures' 5-year high stood at $416,368 during FY2024, with a 5-year trough of $80,790 in FY2023.
  • Over the past 2 years, Orchestra BioMed Holdings' median Gains from Sales and Divestitures value was $248,579 (recorded in 2023), while the average stood at $248,579.
  • Data for Orchestra BioMed Holdings' Gains from Sales and Divestitures shows a peak YoY spiked of 415.37% (in 2024) over the last 5 years.
  • Orchestra BioMed Holdings' Gains from Sales and Divestitures (Yearly) stood at $80,790 in 2023, then surged by 415.37% to $416,368 in 2024.